Catalyst Wire Dossier Catalyst Wire Dossier

Refralon

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Refralon, covering 2025-03-27 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form [Phase 2]

See pricing